ReviewRSC advances2022
Copper sulfide nanostructures: synthesis and biological applications.
Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A Simple and Rapid New Method for Thiolated DNA Modification of Copper Sulfide Nanoparticles: Preparation of Materials for Cancer Photothermal Therapy.Chemistry & biodiversity · 2026Article
- Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy.Materials today. Bio · 2025Review
- Stimuli-Responsive Materials for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Microfluidic-Assisted Silk Nanoparticles Co-Loaded with Epirubicin and Copper Sulphide: A Synergistic Photothermal-Photodynamic Chemotherapy Against Breast Cancer.Nanomaterials (Basel, Switzerland) · 2025Article
- Green synthesis of CuRSC advances · 2025Article
- Recent Trends in Biomedical Applications of CuInternational journal of nanomedicine · 2025Review
- Lnc-MEG8 regulates yak myoblast differentiation via the miR-22-3p/RTL1 axis.BMC genomics · 2024Article
- Au@CuS Nanoshells for Surface-Enhanced Raman Scattering Image-Guided Tumor Photothermal Therapy with Accelerated Hepatobiliary Excretion.Pharmaceutics · 2024Article
- Neurotoxicity and Developmental Neurotoxicity of Copper Sulfide Nanoparticles on a Human Neuronal In-Vitro Test System.International journal of molecular sciences · 2024Article
- Plasmonic porous micro- and nano-materials based on Au/Ag nanostructures developed for photothermal cancer therapy: challenges in clinicalization.Nanoscale advances · 2023Review
- Plasmonic and Photothermal Effects of CuS Nanoparticles Biosynthesized from Acid Mine Drainage with Potential Drug Delivery Applications.International journal of molecular sciences · 2023Article
- Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation.RSC advances · 2023Review
- Development of hierarchical copper sulfide-carbon nanotube (CuS-CNT) composites and utilization of their superior carrier mobility in efficient charge transport towards photodegradation of Rhodamine B under visible light.Nanoscale advances · 2023Article
- Challenges and advances for glioma therapy based on inorganic nanoparticles.Materials today. Bio · 2023Review
- Recent Development of Nanomaterials for Transdermal Drug Delivery.Biomedicines · 2023Review
- Photo-Stimuli-Responsive CuS Nanomaterials as Cutting-Edge Platform Materials for Antibacterial Applications.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past few years, considerable attention has been paid to biomedical applications of copper sulfide nanostructures owing to their enhanced physiochemical and pharmacokinetics characteristics in comparison to gold, silver, and carbon nanomaterials. The small-sized Cu
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.